17
Participants
Start Date
October 31, 2009
Primary Completion Date
September 30, 2014
Study Completion Date
September 30, 2014
Bortezomib
"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.~Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
Huntsman Cancer Institute, Salt Lake City
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
University of Utah
OTHER